AI has become a powerful tool for accelerating clinical trials in the pharmaceutical industry, streamlining processes like site selection and data management. However, as technology advances, experts warn that AI in clinical trials can only go so far. To truly reduce trial timelines, strong foundational practices and effective relationships between sites and sponsors are still essential.
AI’s Role in Trial Acceleration
clinical trial acceleration,Artificial intelligence is transforming the way clinical trials are conducted by helping with early stages like protocol planning, recruitment, and data analysis. It can speed up certain processes, such as identifying suitable sites or managing complex data. However, these technological advancements can only be effective if the fundamentals are in place, including smooth communication and well-established operational practices.
Relationship Challenges Still a Major Pain Point
While AI helps in various aspects like recruitment, retention, and protocol management, relationship issues remain one of the primary causes of delays in clinical trials. Jimmy Bechtel, Chief Site Success Officer for the Society for Clinical Research Sites (SCRS), emphasizes the importance of collaboration and communication between sites and sponsors or contract research organizations (CROs). Without addressing these relationship challenges, trial delays will persist, despite the best efforts of AI tools.
Bechtel points out that both sites and sponsors need effective relationship management practices and transparent communication channels to avoid delays. For instance, ensuring that there is someone available in the same or similar time zone can prevent unnecessary wait times for responses, improving efficiency in the process.
Training Delays Impacting Trial Timelines
Another area contributing to delays is training, which can often be redundant. Sites may be asked to repeat training, even when it’s still valid from a previous study. This repetition adds unnecessary time to the process, delaying enrollment and trial progress. Anusha Shetty, Senior Director of Strategy at Veeva Systems, also highlights this issue, noting that sometimes sites are required to take training that isn’t relevant to their roles in the trial.
Combining AI and Strong Relationships for Faster Trials
clinical trial acceleration,AI has the potential to significantly accelerate clinical trials, but it’s clear that human collaboration remains crucial. Strengthening relationships between sponsors, CROs, and sites, while streamlining training processes, is essential for ensuring that AI’s impact on trial acceleration is fully realized. Only by improving these foundational aspects can the industry achieve truly efficient and rapid clinical trials.
